Sanofi India net moves up by 37.5% in Q1, Charles Billard will be new CFO

New Delhi: Drug firm Sanofi India on Tuesday reported 37.27 per cent rise in net profit to Rs 82.5 crore for the quarter ended March 31, 2018.

The company had posted a net profit of Rs 60.1 crore in January-March period of 2016-17, Sanofi India said in a filing to BSE.

Total revenue from operations also rose to Rs 617.7 crore as against Rs 552.9 crore earlier, it added.

In a separate filing , the company said its board has approved appointment of Charles Billard as Chief Financial Officer and key Managerial Personnel with effect from July 1, 2018.

Shares of Sanofi India were today trading at Rs 4,890.85 per scrip on BSE, up 1.17 per cent from its previous close.

  • Related Posts

    FDA cracks down on illegal drug trade, stock worth about ₹25 lakh seized from Pune and Kolhapur

    Pune: In a major crackdown against illegal pharmaceutical activities that compromise public health, the Food and Drug Administration (FDA) has seized a stock of medicines worth above Rs24.81 lakh from…

    ICMR-NIN study links micronutrient deficiencies to higher dementia risk

    Hyderabad – A groundbreaking study by the Indian Council of Medical Research’s National Institute of Nutrition (ICMR-NIN) has established a clear association between micronutrient deficiencies and elevated dementia risk among Indian…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    FDA cracks down on illegal drug trade, stock worth about ₹25 lakh seized from Pune and Kolhapur

    FDA cracks down on illegal drug trade, stock worth about ₹25 lakh seized from Pune and Kolhapur

    ICMR-NIN study links micronutrient deficiencies to higher dementia risk

    ICMR-NIN study links micronutrient deficiencies to higher dementia risk

    Pvt nursing home sealed in Chatra after woman, unborn baby die

    Pvt nursing home sealed in Chatra after woman, unborn baby die

    30 docs from 9 states guilty of taking pharma company junket, no action yet by 6 state medical councils

    30 docs from 9 states guilty of taking pharma company junket, no action yet by 6 state medical councils

    Scheme to build bulk drugs’ R&D, capacity in works, says Pharma secy

    Scheme to build bulk drugs’ R&D, capacity in works, says Pharma secy

    Drug companies directed to step up vigil on adverse reactions

    Drug companies directed to step up vigil on adverse reactions